First-Line Management of HER2-Mutant Non-Small Cell Lung Cancer in an Older Patient with Hepatic Impairment and Polypharmacy

Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.

Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.

NCCN guidance highlights how HER2-mutant lung cancer may still benefit from chemo‑immunotherapy, as PD‑L1 and response patterns differ from EGFR/ALK/RET/ROS1.

Learn how zangontinib affects statins and liver risk, when to switch to pravastatin, and how to monitor labs remotely for hepatitis B safety.

Learn how zangontinib affects atorvastatin, raises liver-risk, and why frequent LFTs plus entecavir may prevent hepatitis B reactivation.